Oksana Kapustynska

Oksana Kapustynska

Auto-generated profile, based on publicly available information

Oksana Kapustynska

Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2025 in Proceeding of the Shevchenko Scientific Society. Medical Sciences
Verified
Journal Article
Open access
PDF file
OKOksana Kapustynska
Oksana Kapustynska
HSHelen Sklyarova
Helen Sklyarova
NDNataliya Denysenko
Nataliya Denysenko
OCOrest Chemerys
Orest Chemerys
LKLesya Kobylinska
Lesya Kobylinska
SVSandor George Vari
Sandor George Vari
Introduction. Soluble suppression of tumorigenicity 2 (sST2) and galectin-3 are considered markers of myocardial hypertrophy and fibrosis. Changes in their concentrations are observed in cardiovascular diseases, including arterial hypertension. The aim. To determine threshold values of hypertrophy and fibrosis biomarkers, namely sST2 and galectin-3, in patients with arterial hypertension. Materials and methods. A prospective study was conducted on 82 patients with arterial hypertension (AH). Patients were stratified into two groups based on left ventricular mass index (LVMI) values: Group 1 with left ventricular hypertrophy (LVMI > 115 g/m² for men and 90 g/m² for women, n=33) and Group 2 with normal LVMI values (n=27). Results. Patients with left ventricular hypertrophy exhibited significantly elevated sST2 and galectin-3 levels. Direct correlations were observed between LVMI and sST2 values (r=0.6397; p=0.000) and galectin-3 (r=0.5113; p=0.001). Both biomarkers correlated with various cardiac parameters, including interventricular septal thickness at end-diastole, left atrial diameter, left ventricular end-diastolic diameter, and posterior wall thickness at end-diastole (specifically with sST2). With a selected sST2 value of 17.0 ng/ml, the diagnostic method demonstrated 88.33% accuracy, 92.59% specificity, 93.3% positive predictive value, and 83.33% negative predictive value for hypertrophy. At the chosen galectin-3 level of 29.0 ng/ml, the proposed method achieved 72.22% accuracy, 73.68% sensitivity, 70.59% specificity, 73.68% positive predictive value, and 70.59% negative predictive value. In conclusion, measuring sST2 and galectin-3 biomarkers facilitates the evaluation of left ventricular hypertrophy, serving as an additional tool in assessing cardiac dysfunction and indicating diverse developmental pathways.

6 May 2025 in EMERGENCY MEDICINE
Verified
Journal Article
Open access
PDF file
OSO.YE. Sklyarova
O.YE. Sklyarova
TMT.A. Maksymets
T.A. Maksymets
OKO.O. Kapustynskyi
O.O. Kapustynskyi
IYI.A. Yuzych
I.A. Yuzych
OKO.S. Kapustynska
O.S. Kapustynska
YSYe.YA. Sklyarov
Ye.YA. Sklyarov
Background. The main cardiovascular risk factors have been investigated over the past few decades. Key factors include dyslipidemia, high blood pressure, smoking, diabetes mellitus and obesity. According to research data, it is important to examine the significance of the homeostasis model of insulin resistance (HOMA-IR) in the Ukrainian population, particularly among individuals with cardio-metabolic risk factors that lead to the development of atherosclerotic, non-atherosclerotic cardiovascular diseases and metabolic complications. Materials and methods. One hundred and ninety-nine individuals were examined: 152 patients with stage I–II arterial hypertension (AH) and 47 individuals without any previously diagnosed diseases. All patients were stratified into six groups according to the number of components of metabolic syndrome (MetS): group 0 — no components of MetS (12 practically healthy individuals); group 1 — the presence of 1 component of MetS; group 2 — the presence of 2 components of MetS; group 3 — three-component MetS; group 4 — four-component MetS; group 5 — five-component MetS. Results. The involvement of a higher number of MetS components was associated with an increase in the IR marker — HOMA-IR. With an increase in the number of MetS components, the body mass index, waist circumference (WC), uric acid and glycemia indicators increased linearly. The incidence of prediabetes, hyperuricemia and AH increased linearly with an increase in the components of MetS. AH and abdominal obesity were early manifestations of metabolic changes. The statistical differences in cardiometabolic risk are more significant when the HOMA-IR exceeded 1.78. When the threshold was exceeded, a significant increase in WC, ttriglycerides, uric acid and C-reactive protein was found in the observed patient groups, and with HOMA-IR values > 3.89, the probability of detecting MetS signs significantly increases. Conclusions. With an increase in the components of MetS, even at the stage of its formation, an increase in the insulin resistance index — HOMA-IR was observed. Abdominal obesity and AH are the most common manifestations at the stage of MetS formation. The average HOMA-IR value of 3.89 aligns with the criteria of MetS, while HOMA-IR above 1.78 is associated with a significance of cardio-metabolic risk factors such as WC, triglycerides, uric acid and C-reactive protein.

30 May 2023 in EMERGENCY MEDICINE
Verified
Journal Article
Open access
PDF file
OSO.O. Samchuk
O.O. Samchuk
ACA.V. Chetaikina
A.V. Chetaikina
OKO.O. Kapustynskyi
O.O. Kapustynskyi
OKO.S. Kapustynska
O.S. Kapustynska
NMN.V. Matolinets
N.V. Matolinets
ESEu.JA. Sklyarov
Eu.JA. Sklyarov
Background. COVID-19 may cause or worsen cardiac dysfunction and patients with pre-existing cardiovascular disease, including heart failure (HF), who have an increased risk of severe and fatal outcomes of COVID-19. The study aimed to determine the role of soluble suppression of tumorigenesis-2 protein (sST2) and natriuretic peptide test (NT-proBNP) in predicting the severe course and in-hospital mortality of patients with COVID-19 and hypertension. Materials and methods. One hundred and fifteen patients with COVID-19 and hypertension were examined. The determination of sST2 and NT-proBNP in blood serum were done using the enzyme-linked immunosorbent assay. The clinical endpoint was assessed during the hospitalization period (death, hospitalization in the intensive care unit, prolonged hospitalization). The risk of the final event development was calculated for the patients who reached the threshold sST2 concentrations, and, separately, based on the diagnostic values of the NT-proBNP. Results. The cut-off values of sST2 recommended for the diagnosis of HF in our study were reached in 7 (28 %) cases. The risk of final clinical points development in these patients was as follows: OR = 10.67; 95% CI: 1.31–86.9; p = 0.0270. The level of NT-proBNP, which meets the criteria for the diagnosis of HF, was constant in only 10 (11.1 %) individuals (p = 0.0461) and the risk of clinical events developing was equal to OR = 7.0; 95% CI: 1.72–28.6; p = 0.0067. Conclusions. Stratification of patients based on sST2 values, in addition to NT-proBNP parameters, may provide further prognostic value compared to NT-proBNP levels in patients with COVID-19 and HF.

30 March 2022 in Medical Science of Ukraine (MSU)
Verified
Journal Article
Open access
PDF file
OSO.O. Samchuk
O.O. Samchuk
OKO.S. Kapustynska
O.S. Kapustynska
EEE.Ya. Sklyarov E.Ya.
E.Ya. Sklyarov E.Ya.
Relevance. Tissue plays a complex physiological role and may therefore progress to COVID-19 and heart failure. Objective is to evaluate the definition and myocardial biomarkers in a patient with viral disease in combination with obesity and heart failure. Materials and methods. 89 patients with coronavirus COVID-19 and heart failure were examined. All patients underwent anthropometric measurements and calculation of body mass index, general clinical treatment, levels of reactive protein, ferritin, procalcitonin, interleukin-6, as well as myocardial markers NTproBNP and troponin I. Results. Among 89 patients, obesity and overweight were diagnosed in 60.7% of cases (41.6% and 19.1%, respectively) and only 39.3% of the weight was in the normal range. Against the background of obesity on COVID-19 pneumonia and heart failure, a statistical increase in the level of C-reactive protein (87.79 ± 16.16 mg / l) was found in patients with COVID-19 pneumonia and non-obesity heart failure (48.79 ± 8.3; mg / l p = 0.036). The statistical value of the level of troponin I (0.04 (0.00; 0.09) on a gas mask in obese patients was noted) (0.01 (0.00; 0.05) ng / ml; p = 0.024). Conclusion. The growth of C-reactive protein in the body with obesity in pneumonia COVID-19 and heart failure confirms the important role of adipose tissue in induction and maintenance. Ectopic fat depots located in the thickness of the heart may also be involved in the development of inflammatory changes in the myocardium, a laboratory sign that is the growth of troponin I.

30 December 2021 in Medical Science of Ukraine (MSU)
Verified
Journal Article
Open access
PDF file
NPN.K. Pokrovska
N.K. Pokrovska
HSH.M. Shcherbata
H.M. Shcherbata
OKO.S. Kapustynska
O.S. Kapustynska
YSY.YA. Sklyarov
Y.YA. Sklyarov
Relevance. The combination of coronavirus disease (COVID-19) with arterial hypertension (AH) and chronic obstructive pulmonary disease (COPD) is associated with decreased saturation, general clinical signs of inflammation, coagulopathies and worsens the course and prognosis of the disease. That is why it is important to identify all possible risk factors for complicated pathology for the prevention and timely treatment of this category of patients. Objective: to study the feature of coronavirus disease in patients with AH and COPD. Materials and methods. A total of 101 patients aged 30 to 80 years with COVID-19 were examined. The first group included 26 people with COVID-19 and COPD (GOLD 2, groups A, B), and the second group included 75 patients with COVID-19 and AH (I-III stages, 1-3 grade). The parameters of the general blood test, biochemical blood test, coagulation testing, D-dimer, C-reactive protein (CRP), and ferritin in the blood were studied. Results. Patients with COVID-19 and COPD had higher erythrocyte sedimentation rate (p> 0,05) and leukocytosis (p <0,05), as well as increased concentrations of creatinine (p < 0,05) and urea (p < 0,01) that indicates the presence of renal pathology. Patients with COVID-19 and AH had significantly lower prothrombin time (p < 0,05) and international normalized ratio (p < 0,05), as well as a higher prothrombin index (p 0,05), CRP (p> 0,05), and ferritin (p <0,05) was higher in patients of the 2nd group, which indicates a more severe course of coronavirus disease, as well as more high risks of thromboembolic complications. Conclusions. The features of coronavirus disease in patients with hypertension indicate a more severe course of the pathology and a high risk of thromboembolic complications, as evidenced by the procoagulant properties of blood and a high level of D-dimer, CRP, and ferritin. According to the data of clinical and laboratory examinations in patients with COPD and COVID-19, there was a significant increase in creatinine, urea, and leukocytosis, which may indicate the addition of renal pathology.

5 June 2026 in Proceeding of the Shevchenko Scientific Society. Medical Sciences
Verified
Journal Article
Closed access
OSOleg Samchuk
Oleg Samchuk
OKOksana Kapustynska
Oksana Kapustynska
OKOleg Kapustynskyi
Oleg Kapustynskyi
ESEugen Sklyarov
Eugen Sklyarov
The aim: To investigate biomarkers of cardiac dysfunction (soluble ST2, interleukin-33, and NT-proBNP) in combatants after blast injury and compare them with patients diagnosed with chronic heart failure (HF) with preserved and mid-range left ventricular ejection fraction. Methods: A study involved 68 combatants who had sustained blast injuries, aged over 18. The comparison group consisted of patients with chronic HF with preserved and mid-range left ventricular ejection fraction in a compensated state; the control group included 26 apparently healthy individuals. All patients underwent a comprehensive echocardiographic examination. The levels of sST2, interleukin-33, and NT-proBNP were determined by enzyme-linked immunosorbent assay (ELISA, Abcam, Cambridge, UK). Results: Combatants showed a statistically significant increase in soluble sST2 compared to the control group (p=0.0062), which was comparable to the elevation observed in patients with HF (p=0.0930). In contrast to sST2, interleukin-33 levels were significantly lower, with the most substantial decrease observed in the combatant group. This may indicate a degree of depletion or trapping by sST2 decoy receptors in this patient cohort. A separate echocardiographic analysis was conducted. The results demonstrated that dysregulation of the ST2 pathway and reduced interleukin-33 levels were associated with increased left ventricular myocardial hypertrophy compared to the apparently healthy individuals. Discussion of results: Stress can induce systemic inflammation and activate the sympathoadrenal system, potentially impacting the IL-33/sST2 axis and promoting remodeling. It can be hypothesized that the reduced IL-33 levels in military personnel post-injury fail to provide a sufficient cardioprotective effect against pro-hypertrophic changes. IL-33 possesses cardioprotective properties, and sST2 acts as its decoy receptor; therefore, an increase in sST2 and/or a decrease in IL-33 creates an imbalance that may contribute to fibrosis and hypertrophy. This may explain why our study did not find a statistically significant difference in echocardiographic parameters (such as the LVMI) between the combatants and patients with HF with preserved or mid-range LVEF. Conclusions: sST2 is a sensitive biomarker of systemic inflammation, cardiac stretch, and metabolic dysregulation. In the military population, it could serve as a valuable diagnostic and prognostic tool. Further research is needed to evaluate its inclusion in the screening protocols for combatants.